Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
Oncology
|
September 5, 2017
A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma
Soham D Puvvada, José M Guillén-Rodríguez, Xavier I Rivera, et al.
Plos One
|
June 4, 2014
Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2
Daruka Mahadevan, Carla Morales, Laurence S Cooke, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 24, 2017
Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas
Soham D Puvvada, José Guillen-Rodriguez, Abhijeet Kumar, et al.
Leukemia & Lymphoma
|
April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2008
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
Daniel O Persky, Joseph M Unger, Catherine M Spier, et al.
Haematologica
|
January 28, 2021
Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
Adam S Kittai, Scott Best, Bria Thurlow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 23, 2016
Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review
Josephine A Taverna, Seongseok Yun, Jayasree Jonnadula, et al.
Oncology
|
February 23, 2018
Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study
Soham D Puvvada, José M Guillén-Rodríguez, Jessica Yan, et al.
Cancer Research Communications
|
March 6, 2023
Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma
Paul A Hamlin, Vasile Musteata, Steven I Park, et al.
Haematologica
|
January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Daniel O Persky, David Dornan, Bryan H Goldman, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
Oncology
|
September 5, 2017
A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma
Soham D Puvvada, José M Guillén-Rodríguez, Xavier I Rivera, et al.
Plos One
|
June 4, 2014
Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2
Daruka Mahadevan, Carla Morales, Laurence S Cooke, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 24, 2017
Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas
Soham D Puvvada, José Guillen-Rodriguez, Abhijeet Kumar, et al.
Leukemia & Lymphoma
|
April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2008
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
Daniel O Persky, Joseph M Unger, Catherine M Spier, et al.
Haematologica
|
January 28, 2021
Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
Adam S Kittai, Scott Best, Bria Thurlow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 23, 2016
Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review
Josephine A Taverna, Seongseok Yun, Jayasree Jonnadula, et al.
Oncology
|
February 23, 2018
Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study
Soham D Puvvada, José M Guillén-Rodríguez, Jessica Yan, et al.
Cancer Research Communications
|
March 6, 2023
Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma
Paul A Hamlin, Vasile Musteata, Steven I Park, et al.
Haematologica
|
January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Daniel O Persky, David Dornan, Bryan H Goldman, et al.
Page
of 5